Project Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Development of MGLUR5 antagonists to treat fragile X syndrome and autism  

These studies provide the foundation that will allow testing of the hypothesis that mGluR5 antagonists can be an effective treatment of fragile X syndrome (FXS) and other disorders of brain development including autism. This research suggests for the first time a sound scientific rationale for pharmacologic treatment of fragile X syndrome and, potentially, other disorders of brain development such as autism.

2008

Funder National Institutes of Health
Fiscal Year Funding $1,068,100.00
Project Number U01MH078270-02
Principal Investigator Carpenter, Randall
Strategic Plan Question Question 4: Which Treatments And Interventions Will Help? (Interventions)
Strategic Plan Objective 4O. Not specific to Question 4 objectives
Federal or Private? Federal
Institution Seaside Therapeutics, LLC
State/Country Massachusetts
Web Link 1 No URL available.
Web Link 2 No URL available.
Web Link 3 No URL available.
New! History/Related Projects Development of mGluR5 antagonists to treat fragile X syndrome and autism | $1,048,100.00 | 2009 | 5U01MH078270-03